Bionyra Pharma Raises €143 Mn in Series A Round

The company is developing next-generation biologic medicines to treat immune-related inflammatory diseases.

Read Also- Czech startup Grid.online Raises €4 Mn in Round led by DFF Ventures

The funding round was co-led by Jeito Capital and Sofinnova Partners. Other investors, including Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures, also participated in the round.

The company previously raised seed funding from Sofinnova Partners. It was co-founded by Dr. Frédéric Marrache, a former Sanofi R&D executive, who currently serves as the company's CEO.

“More than half of patients suffering from immune-mediated inflammatory diseases remain inadequately controlled, highlighting a significant need for better treatment options. Across our pipeline, we are selectively modulating immune pathways that are central drivers of disease in indications where current therapies remain insufficient,” said Dr. Marrache, Co-founder and CEO of Bionyra. “We have built Bionyra around assets and targets with clear therapeutic rationale, relevant biology and optimized clinical strategy to develop therapies that will deliver meaningful impact to people who don’t currently have good options.”

“So many patients suffering from immune-mediated inflammatory diseases still face daily burden due to limited treatment options,” said Mehdi Ainouche, Partner at Jeito Capital. “Bionyra is uniquely positioned to accelerate delivery of highly promising therapies to patients through a focused and well-designed clinical development strategy aimed at rapidly generating clinical validation and addressing key unmet needs like deeper remission and alternatives for non-responders. We look forward to supporting Frédéric and the entire Bionyra team as the company reaches a pivotal stage in its development while simultaneously building a scalable pipeline in dermatology and IBD.”

“When we co-founded Bionyra with Frédéric, our conviction in both the company and his leadership was grounded in his deep expertise in immune and inflammatory diseases. Today, that conviction is reflected in a $165 million oversubscribed round backed by an exceptional syndicate of investors who share our belief in this pipeline and the team behind it. Looking ahead, we are focused on advancing these programs with the aim of bringing meaningful new treatment options to patients,” said Anta Gkelou, Partner at Sofinnova Partners.

Founded in 2025 by Frédéric Marrache, Bionyra Pharma is a clinical-stage biotech company developing advanced biologic medicines for people with serious immune and inflammatory diseases.

The company is working on new antibody-based treatments designed to provide stronger and longer-lasting disease control. Its initial focus is on conditions such as atopic dermatitis (eczema) and inflammatory bowel disease.

Bionyra was launched with seed funding from Sofinnova Partners and was co-founded by Sofinnova Partners and Dr. Frédéric Marrache, a former Sanofi R&D executive with extensive experience in immunology.

The company's goal is to improve upon existing treatments by creating more effective and convenient therapies that deliver better and longer-lasting results for patients.